NCT07174739 Efficacy of Quantum Molecular Resonance in Neuropathic Corneal Pain and Corneal Nerve Regeneration
| NCT ID | NCT07174739 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Singapore Eye Research Institute |
| Condition | Neuropathic Corneal Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2023-11-01 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2023-11-01 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to evaluate whether Quantum Molecular Resonance (QMR) treatment can effectively reduce eye pain and stimulate corneal nerve regeneration in patients with neuropathic corneal pain (NCP). Participants diagnosed with NCP will attend a total of nine study visits, consisting of one baseline assessment and eight QMR treatment sessions. At each visit, participants will undergo a series of clinical examinations to evaluate changes in the ocular surface, corneal nerves, and tear proteins, and will complete questionnaires regarding their symptoms, eye pain, and quality of life. The investigators will compare these outcomes before and after QMR treatment to determine whether QMR treatment alleviates NCP symptoms and enhances ocular surface and corneal nerve health. The investigators hypothesize that QMR treatment will provide notable pain relief, promote corneal nerve regeneration, and improve overall quality of life for NCP patients.
Eligibility Criteria
Inclusion Criteria: * Be at least 21 years of age. * Regardless of gender (Male/Female). * Regardless of race (Chinese/Malay/Indian/Eurasian/Others). * Diagnosed with neuropathic corneal pain based on the following criteria: presence of neuropathic ocular symptoms (burning, stinging, photophobia, pain, severe dryness), absent or minimal slit-lamp findings to explain the symptoms and corneal nerve abnormalities as detected by IVCM (decreased corneal length and density, presence of neuromas). * Willing to receive all eye examinations in this study. Exclusion Criteria: * Pregnant women. * Participants carrying active implantable devices (e.g., pacemakers and hearing aids). * Oncologic patients under treatment; patient who underwent ocular surgery in the last month. * Participants who had ocular infection within 6 months, or active ocular infection or inflammation; any concomitant ocular diseases that could potentially induce ocular pain, such as uveitis.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07174739 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Neuropathic Corneal Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07174739 currently recruiting?
Yes, NCT07174739 is actively recruiting participants. Contact the research team at liu.yu.chi@snec.com.sg for enrollment information.
Where is the NCT07174739 trial being conducted?
This trial is being conducted at Singapore, Singapore.
Who is sponsoring the NCT07174739 clinical trial?
NCT07174739 is sponsored by Singapore Eye Research Institute. The trial plans to enroll 30 participants.